Frazier William 4

What Happened

• William Frazier, Chief Medical Officer and director of Viemed Healthcare (VMD), reported vesting/conversion of equity awards on 2026-01-29. The filing shows conversions/vestings totaling 3,112 underlying shares (2,334 + 778).
• Of those, 802 shares were withheld by the issuer to satisfy tax withholding (reported value $7.48/share; total ~$5,999) and 778 shares were disposed to the issuer (cash settlement) at $7.48/share (total ~$5,819). The per-share price is based on the market close on 2026-01-29.

Key Details

• Transaction date: January 29, 2026; Form 4 filed February 2, 2026 (appears timely under the two-business-day Form 4 rule).
• Price used for valuation: $7.48 per share (market close on 2026-01-29, per filing).
• Reported disposals: 802 shares withheld for taxes (code F) totaling ~$5,999; 778 shares sold/disposed to issuer (code D) totaling ~$5,819.
• Reported conversions/exercises: entries show exercise/conversion of derivative awards (code M) for 2,334 and 778 shares; related derivative cancellations also reported.
• Shares owned after transaction: not explicitly stated in the provided excerpt. Based on the reported activity, net shares retained = 3,112 vested − 802 withheld − 778 sold = 1,532 shares (calculated from filing entries).
• Footnotes of note:
  • F1–F2: RSUs convert 1:1 to common shares; shares withheld to cover tax withholding.
  • F4–F6: Some awards were cash‑settled phantom share units (economic equivalent of common shares) and were settled for cash, reported as simultaneous acquisition and disposition.

Context

• This was largely a vesting event (RSUs and cash‑settled phantom units), not an open‑market buy or discretionary sale: some shares were withheld for taxes and some were cashed out to the company as part of phantom/share settlement (a type of cashless/cash‑settlement transaction).
• Such withholding and company buybacks on vesting are routine compensation mechanics and do not necessarily reflect the insider’s view of the company’s prospects.